These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 27693013

  • 1. Proposed breakpoint of piperacillin/tazobactam against extended spectrum β-lactamases producing bacteria in bacteremia.
    Sugimoto N, Yamagishi Y, Mikamo H.
    J Infect Chemother; 2017 Jan; 23(1):65-67. PubMed ID: 27693013
    [Abstract] [Full Text] [Related]

  • 2. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
    Tsai HY, Chen YH, Tang HJ, Huang CC, Liao CH, Chu FY, Chuang YC, Sheng WH, Ko WC, Hsueh PR.
    Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
    [Abstract] [Full Text] [Related]

  • 3. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
    Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE, Antibacterial Resistance Leadership Group.
    Clin Infect Dis; 2015 May 01; 60(9):1319-25. PubMed ID: 25586681
    [Abstract] [Full Text] [Related]

  • 4. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ng TM, Khong WX, Harris PN, De PP, Chow A, Tambyah PA, Lye DC.
    PLoS One; 2016 May 01; 11(4):e0153696. PubMed ID: 27104951
    [Abstract] [Full Text] [Related]

  • 5. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ofer-Friedman H, Shefler C, Sharma S, Tirosh A, Tal-Jasper R, Kandipalli D, Sharma S, Bathina P, Kaplansky T, Maskit M, Azouri T, Lazarovitch T, Zaidenstein R, Kaye KS, Marchaim D.
    Infect Control Hosp Epidemiol; 2015 Aug 01; 36(8):981-5. PubMed ID: 25990361
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.
    Peterson LR.
    Clin Microbiol Infect; 2008 Jan 01; 14 Suppl 1():181-4. PubMed ID: 18154544
    [Abstract] [Full Text] [Related]

  • 8. Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli at a Tertiary Hospital.
    Namikawa H, Yamada K, Fujimoto H, Oinuma KI, Tochino Y, Takemoto Y, Kaneko Y, Shuto T, Kakeya H.
    Intern Med; 2017 Jan 01; 56(14):1807-1815. PubMed ID: 28717075
    [Abstract] [Full Text] [Related]

  • 9. The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.
    Tamma PD, Rodriguez-Bano J.
    Clin Infect Dis; 2017 Apr 01; 64(7):972-980. PubMed ID: 28362938
    [Abstract] [Full Text] [Related]

  • 10. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
    Han SB, Jung SW, Bae EY, Lee JW, Lee DG, Chung NG, Jeong DC, Cho B, Kang JH, Kim HK, Park YJ.
    Microb Drug Resist; 2015 Apr 01; 21(2):244-51. PubMed ID: 25398058
    [Abstract] [Full Text] [Related]

  • 11. Superior effect of tazobactam/piperacillin compared to piperacillin on beta-lactamase-producing Pseudomonas aeruginosa.
    Nishida K, Higashitani F, Hyodo A.
    Chemotherapy; 1997 Apr 01; 43(3):171-8. PubMed ID: 9142457
    [Abstract] [Full Text] [Related]

  • 12. Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak.
    Fujita A, Kimura K, Yokoyama S, Jin W, Wachino J, Yamada K, Suematsu H, Yamagishi Y, Mikamo H, Arakawa Y.
    PLoS One; 2015 Apr 01; 10(11):e0142366. PubMed ID: 26539828
    [Abstract] [Full Text] [Related]

  • 13. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.
    D'Angelo RG, Johnson JK, Bork JT, Heil EL.
    Expert Opin Pharmacother; 2016 Apr 01; 17(7):953-67. PubMed ID: 26891857
    [Abstract] [Full Text] [Related]

  • 14. [A comparative study of tazobactam/piperacillin and piperacillin in bacterial pneumonia].
    Oizumi K, Ohno T, Kawahara M, Kawaguchi S, Saisho M, Mitutake Y, Saito A, Tomizawa M, Koike T, Takebe K.
    Jpn J Antibiot; 1995 Apr 01; 48(4):449-81. PubMed ID: 7783313
    [Abstract] [Full Text] [Related]

  • 15. Microbiologic and clinical implications of bacteremia due to extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC beta-lactamase DHA-1.
    Lee CH, Su LH, Li CC, Chien CC, Tang YF, Liu JW.
    Antimicrob Agents Chemother; 2010 Dec 01; 54(12):5395-8. PubMed ID: 20855742
    [Abstract] [Full Text] [Related]

  • 16. [Development of beta-lactamase inhibitors].
    Hyodo A, Higashitani F, Nishida K, Kunugita C, Unemi N.
    Nihon Rinsho; 1997 May 01; 55(5):1272-80. PubMed ID: 9155186
    [Abstract] [Full Text] [Related]

  • 17. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.
    Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC.
    Clin Infect Dis; 2013 Feb 01; 56(4):488-95. PubMed ID: 23090931
    [Abstract] [Full Text] [Related]

  • 18. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L, Picón E, Morillo C, Hernández JR, Docobo F, Pachón J, Rodríguez-Baño J, Pascual A.
    Clin Microbiol Infect; 2010 Feb 01; 16(2):132-6. PubMed ID: 19614715
    [Abstract] [Full Text] [Related]

  • 19. Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
    Yoon YK, Kim JH, Sohn JW, Yang KS, Kim MJ.
    Int J Antimicrob Agents; 2017 Apr 01; 49(4):410-415. PubMed ID: 28263710
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis.
    Hoashi K, Hayama B, Suzuki M, Sakurai A, Takehana K, Enokida T, Takeda K, Ohkushi D, Doi Y, Harada S.
    Microbiol Spectr; 2022 Aug 31; 10(4):e0220622. PubMed ID: 35916524
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.